What Happened
- A study — the FinCan study — by oncologists and health economists from AIIMS Delhi's Dr B.R. Ambedkar Institute Rotary Cancer Hospital has called for significant expansion of cancer coverage under Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB-PMJAY).
- Since its launch in 2018, AB-PMJAY has covered over 68 lakh cancer treatments worth approximately ₹13,000 crore, with over 75% of treatments availed in rural areas — demonstrating reach among low-income populations.
- However, the study found critical gaps: the current annual cap of ₹5 lakh per family is insufficient for high-stage cancers, diagnostics are largely excluded from coverage despite being low-cost, and early detection is not systematically incentivised.
- Key recommendations include a five-year "revolving ceiling" of ₹25 lakh per family, a ₹10 lakh top-up for late-stage cancer patients (about 30–37% of cases), and embedding diagnostic and screening support into the scheme.
- The study projects that faster diagnosis and early treatment initiation could save ₹1,500 crore annually and generate 1,560 additional cancer survivors per year.
Static Topic Bridges
Ayushman Bharat PM-JAY: Architecture and Coverage
Ayushman Bharat PM-JAY was launched on September 23, 2018, at Ranchi, Jharkhand, as a flagship government health insurance scheme targeting the bottom 40% of India's population. It provides a cashless health cover of ₹5 lakh per family per year for secondary and tertiary hospitalisation across empanelled public and private hospitals. The target beneficiary base was 10.74 crore poor and vulnerable families (approximately 50 crore individuals), identified through the Socio-Economic Caste Census (SECC) 2011 database. The scheme is implemented through the National Health Authority (NHA) and is co-funded by the Centre and states (60:40 ratio; 90:10 for NE and special category states).
- Launch date: September 23, 2018 (Ranchi, Jharkhand)
- Coverage: ₹5 lakh per family per year (hospitalisation)
- Target beneficiaries: 10.74 crore families (~50 crore individuals); bottom 40%
- As of 2024: ~8.19 crore people have received treatment under the scheme
- Centre-state funding: 60:40 (90:10 for NE and special category states)
- Implementing body: National Health Authority (NHA)
- Cancer treatments covered: 68+ lakh (₹13,000 crore) since 2018
Connection to this news: The FinCan study reveals that while AB-PMJAY has meaningfully improved cancer care access — especially in rural areas — the ₹5 lakh cap, exclusion of diagnostics, and lack of screening support create structural gaps that limit its impact on India's rising cancer burden.
India's Cancer Burden and the Need for Universal Health Coverage
India faces a rapidly growing cancer burden. The crude incidence rate stands at approximately 100 per 1,00,000 population, with projections showing incidence rising from ~529 per 1,00,000 (2022) toward ~549 per 1,00,000 (2031). Cancer mortality increased by over 46% between 1990 and 2021, with breast cancer now the leading cause of cancer death (overtaking stomach cancer). The economic cost of cancer is concentrated on low-income households — catastrophic health expenditure (spending more than 10% of household income on healthcare) is a leading cause of poverty in India. SDG Target 3.8 requires achieving universal health coverage (UHC), including financial risk protection and access to quality essential health services. AB-PMJAY is India's primary instrument for UHC, but its cancer coverage gaps reveal how far the system still needs to travel.
- SDG 3.8: universal health coverage including financial risk protection
- India cancer incidence: ~100 per 1,00,000 population (National Cancer Registry Programme)
- Fastest-growing cancer: breast cancer (now #1 cause of cancer mortality)
- Catastrophic health expenditure: common for cancer patients outside AB-PMJAY
- Diagnostics: account for only 3% of total cancer care cost yet often fall outside PMJAY coverage
- FinCan recommendation: diagnostics + screening to be included in scheme
Connection to this news: The study directly connects to SDG 3.8 and India's commitment to achieving UHC — demonstrating that coverage without early detection support leads to late-stage presentation, higher costs, and worse outcomes.
India's Comprehensive Primary Health Architecture: HWCs and Screening
The Ayushman Bharat scheme has two components: (1) AB-PMJAY (the insurance component) and (2) Health and Wellness Centres (HWCs). HWCs — over 1.6 lakh of which have been set up — are designed to deliver comprehensive primary health care including screening for non-communicable diseases (NCDs) like cancer, diabetes, and hypertension. Under the National Programme for Non-Communicable Disease Control (NP-NCD), population-based screening for oral, breast, and cervical cancers is a mandated activity at HWCs for adults over 30 years. However, the study points out that this screening activity is not currently integrated with AB-PMJAY's coverage logic — meaning patients identified early at HWCs do not automatically trigger seamless insurance coverage for follow-up treatment.
- HWCs: 1.6 lakh+ established (AB-PMJAY's primary care component)
- NP-NCD: screening for oral, breast, and cervical cancer at HWCs for 30+ adults
- Gap: screening at HWC not linked to AB-PMJAY treatment coverage pathway
- FinCan model: embedding diagnostics + screening into PMJAY could save ₹1,500 crore/year + 1,560 extra survivors/year
Connection to this news: The FinCan study's core recommendation — integrating diagnostics and screening support into AB-PMJAY — is essentially an argument for connecting the two existing pillars of Ayushman Bharat into a seamless continuum from early detection to treatment.
Key Facts & Data
- AB-PMJAY launch: September 23, 2018
- Coverage: ₹5 lakh per family per year (hospitalisation)
- Cancer treatments covered: 68 lakh+ worth ₹13,000 crore since 2018
- Rural share: 75%+ of cancer treatments under PMJAY availed by rural populations
- FinCan study: AIIMS Delhi / Dr B.R. Ambedkar Institute Rotary Cancer Hospital
- Recommendation: ₹25 lakh five-year revolving ceiling + ₹10 lakh top-up for late-stage (30–37% of patients)
- Projected impact: ₹1,500 crore savings/year + 1,560 additional survivors/year
- India cancer incidence: ~529 per 1,00,000 (2022), rising to ~549 by 2031
- Diagnostics share: 3% of total cancer care cost; largely outside current PMJAY coverage
- HWCs: 1.6 lakh+ established; screen for oral, breast, cervical cancers